Batavia Biosciences, a contract development and manufacturing organization, has partnered with ChromaTan, Inc. for the development and integration of BioRMB (formerly known as Continuous Countercurrent Tangential Chromatography or CCTC) technology into Batavia’s AAV HIP-Vax manufacturing platform. The project aims to improve AAV manufacturing and reduce manufacturing costs through process intensification.
Recombinant adeno-associated virus (rAAV) vectors are spearheading the development of next generation treatments for debilitating and life-threatening disorders. However, demand for rAAV is exceeding production capacity.
Continuous chromatography has been shown to greatly contribute to the intensification of manufacturing processes for monoclonal antibodies. Batavia Biosciences expects to increase its rAAV production capacity and to further reduce the associated cost of goods through integration of ChromaTan’s BioRMB – a novel column-free real moving bed continuous chromatography platform – into Batavia’s proprietary HIP-Vax manufacturing platform.
“The promise of next generation platforms both upstream and downstream in the field of gene therapy is very powerful for multiple reasons such as improvements in manufacturability, process economics, improved recovery and product quality. This exciting partnership enabled by NIIMBL, will empower us to take that idea a step further – by directly integrating these hyper efficient next generation platforms we have the potential to transform rAAV manufacturing as we know it,” said Oleg Shinkazh, Chief Technical officer at Chromatan.
Peter Abbink, Managing Director at Batavia Biosciences, Inc., said, “At Batavia, we continuously seek innovative solutions to fuel our mission to enhance the accessibility and availability of critical life-changing treatments. We are privileged to have the backing of NIIMBL and are thrilled to embark on a productive partnership with ChromaTan on this endeavor.”
This project was developed with an award from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance from the U.S. Department of Commerce, National Institute of Standards and Technology.

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
